IKS012
/ Iksuda Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 08, 2024
IKS012, a novel ADC design with favorable efficacy and safety for treatment of Folate Receptor Alpha-positive cancers
(EORTC-NCI-AACR 2024)
- "In the IGROV-1 model, IKS012 showed improved efficacy over MORAb-202, an eribulin ADC with a cathepsin cleavable linker...In the OVCAR-3 model, a single dose of 5 mg/kg IKS012 induced 75% TGI on day 35 in comparison to 42% and 68% TGI for the Elahere analogue and MORAb-202, respectively... The IKS012 ADC design with stable PermaLink® conjugation and the selective glucuronide trigger confers a favorable preclinical anti-tumor activity and safety profile. Our findings support the clinical development of IKS012 for the treatment of FRα-positive solid cancers."
Clinical • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CTSB • CTSC • FOLR1
June 07, 2021
Iksuda Therapeutics Closes $47 Million Financing Round
(Businesswire)
- “Iksuda Therapeutics….announced it has completed a US $47 million (circa GB £34 million) financing round…The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies…The investment will enable progression of IKS03 to first-in-human phase 1 clinical trials. It will also be used to accelerate the Company’s earlier-stage programmes including IKS04 and IKS012 to IND filing.”
Financing • Oncology
1 to 2
Of
2
Go to page
1